194 related articles for article (PubMed ID: 19255312)
1. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Miller AA; Murry DJ; Owzar K; Hollis DR; Kennedy EB; Abou-Alfa G; Desai A; Hwang J; Villalona-Calero MA; Dees EC; Lewis LD; Fakih MG; Edelman MJ; Millard F; Frank RC; Hohl RJ; Ratain MJ
J Clin Oncol; 2009 Apr; 27(11):1800-5. PubMed ID: 19255312
[TBL] [Abstract][Full Text] [Related]
2. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Shinsako K; Mizuno T; Terada T; Watanabe J; Kamba T; Nakamura E; Ogawa O; Inui K
Int J Clin Oncol; 2010 Oct; 15(5):512-4. PubMed ID: 20340037
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Synold TW; Takimoto CH; Doroshow JH; Gandara D; Mani S; Remick SC; Mulkerin DL; Hamilton A; Sharma S; Ramanathan RK; Lenz HJ; Graham M; Longmate J; Kaufman BM; Ivy P;
Clin Cancer Res; 2007 Jun; 13(12):3660-6. PubMed ID: 17575231
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
[TBL] [Abstract][Full Text] [Related]
8. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Brendel E; Ludwig M; Lathia C; Robert C; Ropert S; Soria JC; Armand JP
Cancer Chemother Pharmacol; 2011 Jul; 68(1):53-61. PubMed ID: 20821331
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
Niwakawa M; Hashine K; Yamaguchi R; Fujii H; Hamamoto Y; Fukino K; Tanigawa T; Sumiyoshi Y
Invest New Drugs; 2012 Jun; 30(3):1046-54. PubMed ID: 21246251
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Keating GM; Santoro A
Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Miller AA; Murry DJ; Owzar K; Hollis DR; Lewis LD; Kindler HL; Marshall JL; Villalona-Calero MA; Edelman MJ; Hohl RJ; Lichtman SM; Ratain MJ
J Clin Oncol; 2007 Jul; 25(21):3055-60. PubMed ID: 17634483
[TBL] [Abstract][Full Text] [Related]
15. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Kim A; McCully C; Cruz R; Cole DE; Fox E; Balis FM; Widemann BC
Invest New Drugs; 2012 Apr; 30(2):524-8. PubMed ID: 21072558
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Kredtke S; Voliotis D; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):620-1. PubMed ID: 14692720
[No Abstract] [Full Text] [Related]
18. Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Pécuchet N; Lebbe C; Mir O; Billemont B; Blanchet B; Franck N; Viguier M; Coriat R; Tod M; Avril MF; Goldwasser F
Br J Cancer; 2012 Jul; 107(3):455-61. PubMed ID: 22767146
[TBL] [Abstract][Full Text] [Related]
19. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Boudou-Rouquette P; Ropert S; Mir O; Coriat R; Billemont B; Tod M; Cabanes L; Franck N; Blanchet B; Goldwasser F
Oncologist; 2012; 17(9):1204-12. PubMed ID: 22752067
[TBL] [Abstract][Full Text] [Related]
20. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]